In Short: Revolutionising Small Molecule API Manufacturing: Embracing Miniaturisation and Automation

In this enlightening episode, Adrian La Porta, Technical Director
at Bryden Wood, dives deep into the evolving landscape of
pharmaceutical manufacturing, focusing on the critical role of
Small Molecule Active Pharmaceutical Ingredients (APIs) in modern
medicine. As the backbone of the world's most essential
medications, the development and production of APIs stand at a
crossroads, challenged by the increasing demand for more complex,
potent, and targeted molecules. Adrian unveils the limitations of
traditional batch chemistry in API manufacturing and explores the
revolutionary shift towards miniaturisation, process
intensification, and automation. 

Join Adrian as he dissects the groundbreaking technologies
reshaping R&D, highlights the inefficiencies of current
manufacturing networks, and proposes a new paradigm that promises
lean, agile, and environmentally sustainable drug production. He
examines the potential of continuous processing and other
intensification strategies to enhance chemistry, reduce waste,
and improve quality, all while addressing the financial and
environmental costs associated with conventional large-scale
manufacturing.

This episode is a must-listen for anyone interested in the future
of pharmaceuticals, from industry professionals and researchers
to healthcare providers and patients. 

Discover how discarding outdated methodologies in favour of
innovative, modular manufacturing systems can transform the
production of life-saving drugs, making them faster, safer, and
more accessible to patients worldwide. 


Send us a text


To learn more about Bryden Wood's Design to Value philosophy,
visit www.brydenwood.com. You can also follow Bryden Wood on
LinkedIn and X.